AI system develops features of complex brains
An AI system could be used to observe how physical constraints shape brains and impact people with cognitive difficulties.
List view / Grid view
An AI system could be used to observe how physical constraints shape brains and impact people with cognitive difficulties.
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
PrecisionLife’s Dr Sayoni Das, a computational biologist who leads the research and development of bioinformatics pipelines that generate biological insights from PrecisionLife’s core technology and support drug discovery programmes, details a new study. Using combinatorial analysis, genetic variants associated with long COVID have been identified and, furthermore, it has been…
In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…
Intestinal organoids allowed researchers to understand how Rnf43 and Daam1 influence the balance of stem cell renewal and differentiation.
Researchers have found what triggers bacteria to start the CBASS immune response to counter infections by phages.
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities.
A continuous sorting technique of stem cells on a DLD microfluidic platform may greatly advance cell therapy.
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…
Drug Target Review’s Taylor Mixides met with Dr Michelle Sidor, the Director of Neuroscience at Alchemab Therapeutics, and Dr Sifis Pediaditakis at the Society for Neuroscience event this November. This exclusive interview explores neuroscientific research and its pivotal role in steering the company toward future triumphs. Michelle highlights the dynamic…
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline…
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Novel approaches to brain disorder diagnosis and treatment may be developed following a project to form a map of the mouse hippocampus.
Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…